Atopic dermatitis is a skin disease characterized by inflammation, pruritus, and chronic or relapsing\neczematous lesions. Recently, ampholytic polysaccharide sacran has attracted a particular\nfocus of attention as a novel biomaterial. In the present study, we investigated the effect of sacran\nsolution on atopic dermatitis in the clinical study. Almost all of the average scores for atopic dermatitis\nsymptoms of each patient treated with sacran solutions were improved. In addition, the\nscores of sleep disorder and itching were also significantly ameliorated by the sacran treatment\nfor 4 weeks, compared with those of initial states. In immatured dermal skin model stimulated\nwith 2,4-dinitrofluorobenzene (DNFB), the sacran treatment markedly down-regulated inflammatory\ncytokine and chemokine mRNA levels such as MCP-1, TNF-, IL-1, and IL-6 mRNAs, compared\nwith that of DNFB alone. Furthermore, a sacran solution significantly suppressed the mRNA\nexpression of TNF- and COX-2 in RAW264.7 cells, a murine macrophage-like cell line, stimulated\nwith phorbol-12-myristate-13-acetate (PMA). In RBL-2H3 cells, a rat basophilic leukemia cell line,\na sacran solution significantly lowered -hexosaminidase release, indicating the suppression of\nallergic response. These results suggest that a sacran solution may have the potential to improve\natopic dermatitis through the impairment of production of inflammatory cytokine and chemokine\nmRNA.
Loading....